SSTR2 and adenocarcinoma: Small-scale clinical studies on its use for adenocarcinoma of other origin [21,22] and preclinical studies on the use of lanreotide in pancreatic ductal adenocarcinoma [23] showed no effect on tumor size and growth even after in vitro SSTR2 gene transfer, although SSTR2 gene transfer itself led to inhibition of tumor growth.